Skip to Content

Y-mAbs Therapeutics Inc

Rating as of

Company Profile

Business Description

Y-mAbs Therapeutics Inc is a late-stage clinical biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. Products developed by the company include naxitamab for the treatment of pediatric patients with relapsed or refractory and radiolabeled omburtamab for the treatment of pediatric patients with central nervous system.

Contact
230 Park Avenue, Suite 3350
New York, NY, 10169
T +1 646 885-8505
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Mar 31, 2020
Fiscal Year End Dec 31, 2019
Stock Type Distressed
Employees 65